Immunovant, Inc. (IMVT) Social Stream

Featured Post From StockTwits About IMVT

$SIOX $MAAC $IMVT For intepirdine, isn’t SIOX (f/k/a Axovant) the company that agree to pay GlaxoSmithKline $5M upfront, $160M milestones if comes to market, and 12.5% royalty fees?

Vivek Ramaswamy says that taking on projects later in their development cycle is what provides Roivant Sciences with a sustainable competitive advantage; and, many failed drugs are simply one short phase 3 study away from FDA approval.

He has also stated Alzheimers is the single greatest health threat to the economy. Yes … Axovant was unsuccessful with intepirdine. However, could intepirdine be a game changer?

If SIOX has the development and commercialization rights, it’s hard to believe Roivant isn’t going to acquire for strategic purposes (i) those rights or (ii) all of SIOX ... in connection with Roivant’s commitment to the field of dementia.

Roivant already has a significant ownership interest in SIOX.

What Else are IMVT Traders Talking About?

Other tickers frequently mentioned alongside IMVT is SIOX.